Cited by 374Psychedelics and Drug StudiesNeurotransmitter Receptor Influence on BehaviorHallucinations in medical conditions

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Serotonin and Hallucinogens

Aghajanian, G·1999·Neuropsychopharmacology

DOI 10.1016/s0893-133x(98)00135-3

Open this paper in CoChat — free account

Abstract

This brief review traces the serotonin (5-HT) hypothesis of the action of hallucinogenic drugs from the early 1950s to the present day. There is now converging evidence from biochemical, electrophysiological, and behavioral studies that the two major classes of psychedelic hallucinogens, the indoleamines (e.g., LSD) and the phenethylamines (e.g., mescaline), have a common site of action as partial agonists at 5-HT2A and other 5-HT2 receptors in the central nervous system. The noradrenergic locus coeruleus and the cerebral cortex are among the regions where hallucinogens have prominent effects through their actions upon a 5-HT2A receptors. Recently, we have observed a novel effect of hallucinogens--a 5-HT2A receptor-mediated enhancement of nonsynchronous, late components of glutamatergic excitatory postsynaptic potentials at apical dendrites of layer V cortical pyramidal cells. We propose that an effect of hallucinogens upon glutamatergic transmission in the cerebral cortex may be responsible for the higher-level cognitive, perceptual, and affective distortions produced by these drugs.

Integrity signals

Registry

Crossref · 10.1016/s0893-133x(98)00135-3

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS.
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).
Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., Saxena, P. R., & Humphrey, P. P. A. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06783-3 · Cited by 3,025
Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors
Pazos, Á., & Palacios, J. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90856-x · Cited by 1,855
Nonrepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli
Aston‐Jones, G., & Bloom, F. E. (1981) · Journal of Neuroscience · doi:10.1523/jneurosci.01-08-00887.1981 · Cited by 1,072
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex
Araneda, R. C., & Andrade, R. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90128-b · Cited by 621
A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS
Woolley, D. W., & Shaw, E. (1954) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.40.4.228 · Cited by 603
SERUM VASOCONSTRICTOR (SEROTONIN)
Rapport, M. M., Green, A. A., & Page, I. H. (1948) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)57137-4 · Cited by 552
5-Hydroxytryptamine 2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites
Jakab, R. L., & Goldman-Rakic, P. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.735 · Cited by 536
Serotonin Content of Some Mammalian Tissues and Urine and a Method for Its Determination
Twarog, B. M., & Page, I. H. (1953) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1953.175.1.157 · Cited by 532

Show all 45 references

Sorted by citations

Molecular, pharmacological and functional diversity of 5-HT receptors
Hoyer, D., Hannon, J. P., & Martin, G. R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00746-8 · Cited by 1,898
Psychedelics
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Serotonin Receptors
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895
Opponent interactions between serotonin and dopamine
Daw, N. D., Kakade, S., & Dayan, P. (2002) · Neural Networks · doi:10.1016/s0893-6080(02)00052-7 · Cited by 844
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Effects of Ketamine in Normal and Schizophrenic Volunteers
Lahti, A. C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674
Mechanisms of synesthesia: cognitive and physiological constraints
Grossenbacher, P. G., & Lovelace, C. T. (2001) · Trends in Cognitive Sciences · doi:10.1016/s1364-6613(00)01571-0 · Cited by 531
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529
Self-citation
Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Psychobiology of Altered States of Consciousness.
Vaitl, D., Birbaumer, N., Gruzelier, J., Jamieson, G. A., Kotchoubey, B., Kübler, A., Lehmann, D., Miltner, W. H. R., Ott, U., Pütz, P., et al. (2005) · Psychological Bulletin · doi:10.1037/0033-2909.131.1.98 · Cited by 448
Serotonin research: contributions to understanding psychoses
GEYER, M., & VOLLENWEIDER, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.006 · Cited by 427
The neural basis of the complex mental task of meditation: neurotransmitter and neurochemical considerations
Newberg, A. B., & Iversen, J. R. (2003) · Medical Hypotheses · doi:10.1016/s0306-9877(03)00175-0 · Cited by 352
A systems model of altered consciousness: integrating natural and drug-induced psychoses
Vollenweider, F. X., & Geyer, M. A. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00646-3 · Cited by 339
The Physiological Role of 5-HT2AReceptors in Working Memory
Williams, G. V., Rao, S. G., & Goldman-Rakic, P. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02843.2002 · Cited by 311
Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex
González-Maeso, J., Yuen, T., Ebersole, B. J., Wurmbach, E., Lira, A., Zhou, M., Weisstaub, N., Hen, R., Gingrich, J. A., & Sealfon, S. C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08836.2003 · Cited by 297
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
López‐Giménez, J. F., & González‐Maeso, J. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_478 · Cited by 325
Pharmacogenetics and the serotonin system: initial studies and future directions
Veenstra-VanderWeele, J. M., Anderson, G. M., & Cook, E. H. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00814-1 · Cited by 292
Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation
Bockaert, J., Claeysen, S., Bécamel, C., Dumuis, A., & Marin, P. (2006) · Cell and Tissue Research · doi:10.1007/s00441-006-0286-1 · Cited by 285
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics.
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
Neuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268
Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.35 · Cited by 266
Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
Majić, T., Schmidt, T. T., & Gallinat, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568040 · Cited by 278
Mismatch negativity predicts psychotic experiences induced by nmda receptor antagonist in healthy volunteers
Umbricht, D., Koller, R., Vollenweider, F. X., & Schmid, L. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01242-2 · Cited by 258
The Mechanistic Classification of Addictive Drugs
Lüscher, C., & Ungless, M. A. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030437 · Cited by 255
Dimers and beyond: The functional puzzles of class C GPCRs
Kniazeff, J., Prézeau, L., Rondard, P., Pin, J., & Goudet, C. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.006 · Cited by 248
The Serotonin System and Spiritual Experiences
Borg, J., Andrée, B., Söderström, H., & Farde, L. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.1965 · Cited by 243
Synaptic plasticity and mental health: methods, challenges and opportunities
Appelbaum, L. G., Shenasa, M. A., Stolz, L., & Daskalakis, Z. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01370-w · Cited by 240
Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex
Béïque, J.-C., Imad, M., Mladenovic, L., Gingrich, J. A., & Andrade, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700436104 · Cited by 229
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
The behavioral pharmacology of hallucinogens
Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.018 · Cited by 238
Psychedelic-inspired drug discovery using an engineered biosensor
Dong, C., Ly, C., Dunlap, L. E., Vargas, M. V., Sun, J., Hwang, I.-W., Azinfar, A., Oh, W. C., Wetsel, W. C., Olson, D. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.043 · Cited by 213
Brain serotonergic circuitries
Charnay, Y., & Léger, L. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.4/ycharnay · Cited by 211
Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia
Castner, S. A., Goldman‐Rakic, P. S., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1710-9 · Cited by 211
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders
Pinares-Garcia, P., Stratikopoulos, M., Zagato, A., Loke, H., & Lee, J. (2018) · Brain Sciences · doi:10.3390/brainsci8080154 · Cited by 200
Serotonin 5-HT2 receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus
Liu, R., Jolas, T., & Aghajanian, G. K. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02468-9 · Cited by 197
Self-citation
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
Garcia‐Romeu, A., & Richards, W. A. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1486289 · Cited by 210
Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia
Umbricht, D., Vollenweider, F. X., Schmid, L., Grübel, C., Skrabo, A., Huber, T., & Koller, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300005 · Cited by 187
Serotonin, But Not N -Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo
Schmid, C. L., & Bohn, L. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1665-10.2010 · Cited by 181
DARPP-32 mediates the actions of multiple drugs of abuse
Svenningsson, P., Nairn, A. C., & Greengard, P. (2005) · The AAPS Journal · doi:10.1208/aapsj070235 · Cited by 174
A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain
Nichols, C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00405-5 · Cited by 163
Functional Internal Complexity of Amygdala: Focus on Gene Activity Mapping After Behavioral Training and Drugs of Abuse
Knapska, E., Radwańska, K., Werka, T., & Kaczmarek, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00037.2006 · Cited by 161
Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities
Szabo, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00358 · Cited by 150
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats
Fantegrossi, W. E., Harrington, A. W., Kiessel, C. L., Eckler, J. R., Rabin, R. A., Winter, J. C., Coop, A., Rice, K. C., & Woods, J. H. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.12.015 · Cited by 145
Pharmacology of stimulants prohibited by the World Anti‐Doping Agency (WADA)
Docherty, J. R. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.124 · Cited by 143
Dimensions of consciousness and the psychedelic state
Bayne, T., & Carter, O. (2018) · Neuroscience of Consciousness · doi:10.1093/nc/niy008 · Cited by 142
The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment
Reynolds, G. P., Templeman, L. A., & Zhang, Z. J. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.019 · Cited by 142
PSD-95 Is Essential for Hallucinogen and Atypical Antipsychotic Drug Actions at Serotonin Receptors
Abbas, A. I., Yadav, P. N., Yao, W.-D., Arbuckle, M. I., Grant, S. G. N., Caron, M. G., & Roth, B. L. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1090-09.2009 · Cited by 141
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences
Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4769-4 · Cited by 133
Brain mechanisms of hallucinogens and entactogens
Vollenweider, F. X. (2001) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2001.3.4/fxvollenweider · Cited by 129
Of Roots and Fruits: A Comparison of Psychedelic and Nonpsychedelic Mystical Experiences
Yaden, D. B., Nguyen, K. D. L., Kern, M. L., Belser, A., Eichstaedt, J. C., Iwry, J., Smith, M. E., Wintering, N., Hood, R. W., & Newberg, A. B. (2016) · Journal of Humanistic Psychology · doi:10.1177/0022167816674625 · Cited by 126
The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats
Scruggs, J. L., Schmidt, D. E., & Deutch, A. Y. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00547-0 · Cited by 126
Enhanced sensory perception in synaesthesia
Banissy, M. J., Walsh, V., & Ward, J. (2009) · Experimental Brain Research · doi:10.1007/s00221-009-1888-0 · Cited by 128
Cognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targets
Terry, A. V., Buccafusco, J. J., & Wilson, C. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.12.006 · Cited by 122
Serotonin Evokes Endocannabinoid Release and Retrogradely Suppresses Excitatory Synapses
Best, A. R., & Regehr, W. G. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0678-08.2008 · Cited by 123
Lysergic acid diethylamide and [−]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex
Muschamp, J. W., Regina, M. J., Hull, E. M., Winter, J. C., & Rabin, R. A. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.044 · Cited by 119
Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine
Jacob, M., & Presti, D. E. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2004.11.005 · Cited by 124
Associations Between Duration of Illicit Drug Use and Health Conditions: Results from the 2005–2007 National Surveys on Drug Use and Health
Han, B., Gfroerer, J., & Colliver, J. D. (2010) · Annals of Epidemiology · doi:10.1016/j.annepidem.2010.01.003 · Cited by 117
A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug
Rose, S. R., Poklis, J. L., & Poklis, A. (2013) · Clinical Toxicology · doi:10.3109/15563650.2013.772191 · Cited by 113
Functional crosstalk between GPCRs: with or without oligomerization
Prézeau, L., Rives, M., Comps‐Agrar, L., Maurel, D., Kniazeff, J., & Pin, J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.10.009 · Cited by 111
Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition
Barrett, F. S., Carbonaro, T. M., Hurwitz, E., Johnson, M. W., & Griffiths, R. R. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4981-x · Cited by 109
The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain
Bray, N. J., Buckland, P. R., Hall, H., Owen, M. J., & O’Donovan, M. C. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001366 · Cited by 108
Similar ultrastructural distribution of the 5-HT2A serotonin receptor and microtubule-associated protein MAP1A in cortical dendrites of adult rat
Cornea-Hébert, V., Watkins, K. C., Roth, B. L., Kroeze, W. K., Gaudreau, P., Leclerc, N. M., & Descarries, L. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00146-x · Cited by 106
Effect of LSD on Prepulse Inhibition and Spontaneous Behavior in the Rat A Pharmacological Analysis and Comparison between Two Rat Strains
Ouagazzal, A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00282-2 · Cited by 103
The Selective Serotonin-2A Receptor Antagonist M100907 Reverses Behavioral Deficits in Dopamine Transporter Knockout Mice
Barr, A. M., Lehmann-Masten, V., Paulus, M., Gainetdinov, R. R., Caron, M. G., & Geyer, M. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300343 · Cited by 103
Is our brain hardwired to produce God, or is our brain hardwired to perceive God? A systematic review on the role of the brain in mediating religious experience
Fingelkurts, A. A., & Fingelkurts, A. A. (2009) · Cognitive Processing · doi:10.1007/s10339-009-0261-3 · Cited by 104
Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions
Dinis‐Oliveira, R. J., Pereira, C. L., & da Silva, D. D. (2018) · Current Molecular Pharmacology · doi:10.2174/1874467211666181010154139 · Cited by 101
Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys
Fantegrossi, W. E., Woods, J. H., & Winger, G. (2004) · Behavioural Pharmacology · doi:10.1097/00008877-200403000-00007 · Cited by 101
Synthesis of a Tricyclic Mescaline Analogue by Catalytic C−H Bond Activation
Ahrendt, K. A., Bergman, R. G., & Ellman, J. A. (2003) · Organic Letters · doi:10.1021/ol034228d · Cited by 99
Enantiospecific Synthesis and Pharmacological Evaluation of a Series of Super-Potent, Conformationally Restricted 5-HT2A/2C Receptor Agonists
Chambers, J. J., Kurrasch‐Orbaugh, D. M., Parker, M., & Nichols, D. E. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000491y · Cited by 98
The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review
Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.023 · Cited by 97
Widespread increases of cortical serotonin type 2A receptor availability after hormone therapy in euthymic postmenopausal women
Moses‐Kolko, E. L., Berga, S. L., Greer, P. J., Smith, G. S., MELTZER, C. C., & Drevets, W. C. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00973-7 · Cited by 96
Transcranial Magnetic Stimulation in Clinical Psychiatry
Belmaker, R. H. (2006) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615377510 · Cited by 96
Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia
Fell, M. J., McKinzie, D. L., Monn, J. A., & Svensson, K. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.007 · Cited by 90
High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens
Reissig, C. J., Carter, L. P., Johnson, M. W., Mintzer, M. Z., Klinedinst, M. A., & Griffiths, R. R. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2680-6 · Cited by 91
5-hydroxytryptamine2A receptors regulate sympathetic nerves constricting the cutaneous vascular bed in rabbits and rats
Blessing, W. W., & Seaman, B. W. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00810-2 · Cited by 88
5-HIAA as a Potential Biological Marker for Neurological and Psychiatric Disorders
Jayamohananan, H., Kumar, M. K. M., & Aneesh, T. P. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.044 · Cited by 88
Olfactory-induced synesthesias: A review and model.
Stevenson, R. J., & Tomiczek, C. (2007) · Psychological Bulletin · doi:10.1037/0033-2909.133.2.294 · Cited by 86
In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or “Ecstasy”) and Hallucinogen Users
Erritzøe, D., Frøkjær, V. G., Holst, K. K., Christoffersen, M. V., Johansen, S. S., Svarer, C., Madsen, J., Rasmussen, P. M., Ramsøy, T. Z., Jernigan, T. L., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.56 · Cited by 84
Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration
Nichols, C. D., Garcia, E. E., & Sanders-Bush, E. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(03)00029-9 · Cited by 82
NBOMes–Highly Potent and Toxic Alternatives of LSD
Zawilska, J. B., Kacela, M., & Adamowicz, P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00078 · Cited by 80
Cortical excitability in neuroleptic-naive first-episode schizophrenic patients
Eichhammer, P., Wiegand, R., Kharraz, A., Langguth, B., Binder, H., & Hajak, G. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00223-8 · Cited by 79
Serotonergic/glutamatergic interactions: the effects of mGlu 2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli
Winter, J. C., Eckler, J. R., & Rabin, R. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1636-2 · Cited by 79
Role of Gq protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
Garcia, E. E., Smith, R. L., & Sanders‐Bush, E. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.03.013 · Cited by 78
Do dorsal raphe 5-HT neurons encode “beneficialness”?
Luo, M., Li, Y., & Zhong, W. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.08.008 · Cited by 81
Effect of Some Psychoactive Drugs Used as ‘Legal Highs’ on Brain Neurotransmitters
Gołembiowska, K., Jurczak, A., Kamińska, K., Noworyta, K., & Górska, A. M. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9569-1 · Cited by 75
Fungal Hallucinogens Psilocin, Ibotenic Acid, and Muscimol
Stebelska, K. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31828741a5 · Cited by 76
5-Hydroxytryptamine 2C (5-HT2C) Receptor Agonists as Potential Antiobesity Agents
Nilsson, B. M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm058240i · Cited by 75
Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns
Garza, R. D. L., Fabrizio, K., & Gupta, A. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0255-5 · Cited by 74
Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser280 by Hallucinogenic versus Nonhallucinogenic Agonists
Karaki, S., Bécamel, C., Murat, S., la Cour, C. M., Millan, M. J., Prézeau, L., Bockaert, J., Marin, P., & Vandermoere, F. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.036558 · Cited by 74
Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats
Fantegrossi, W. E., Harrington, A. W., Eckler, J. R., Arshad, S., Rabin, R. A., Winter, J. C., Coop, A., Rice, K. C., & Woods, J. H. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0009-4 · Cited by 74
Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines
Winter, J. C. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1356-8 · Cited by 65
Clozapine Reverses Hyperthermia and Sympathetically Mediated Cutaneous Vasoconstriction Induced by 3,4-Methylenedioxymethamphetamine (Ecstasy) in Rabbits and Rats
Blessing, W. W., Seaman, B. W., Pedersen, N. P., & Ootsuka, Y. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06385.2003 · Cited by 72
Neuroscience and Biobehavioral Reviews
Fitzgibbon, B. M., Enticott, P. G., Rich, A. N., Giummarra, M. J., Georgiou‐Karistianis, N., & Bradshaw, J. L. (2011) · Cited by 72
Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents
Fantegrossi, W. E., Reissig, C. J., KATZ, E., Yarosh, H. L., Rice, K. C., & WINTER, J. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.09.007 · Cited by 72

Authors: Aghajanian, G.
Affiliations: Yale University (US)
Corresponding author: Aghajanian, G
Venue: Neuropsychopharmacology
Publisher: Springer Science and Business Media LLC
Published: 1999-08
Volume: 21
Issue: 2
Pages: 16S-23S
ISSN: 0893-133X (ISSN-L)
DOI: 10.1016/s0893-133x(98)00135-3
OpenAlex: W2075352853
Cited by: 371
References: 45
Citations by year: 2026: 8 · 2025: 5 · 2024: 6 · 2023: 11 · 2022: 13 · 2021: 11 · 2020: 9 · 2019: 10 · 2018: 18 · 2017: 17 · 2016: 15 · 2015: 13 · 2014: 12 · 2013: 14 · 2012: 8
FWCI: 3.97
Type: journal article
Language: en
Open access: closed
Locations: Neuropsychopharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Mental Health
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
Keywords: serotonin, hallucinogens, 5-HT2A receptor, psychedelics, indoleamines, phenethylamines, LSD, mescaline, locus coeruleus, cerebral cortex, glutamatergic neurotransmission, excitatory postsynaptic potentials, cortical pyramidal neurons
MeSH terms: Animals, Cerebral Cortex, Hallucinogens, Humans, Synaptic Transmission, Receptors, Serotonin, Serotonin, Pyramidal Cells, Receptor, Serotonin, 5-HT2A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Serotonin and Hallucinogens

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks